Back

Sustained exposure to CAR-T cell secretome impairs human Hematopoietic Stem Cell function and is reversible by dual TNFα-IFNγ blockade

Muddineni, S. S. N. A.; Rasoulouniriana, D.; Meir, A.; Geller, D.; Singha Roy, D.; Tako, E.; Solomon, N.; Avraham, T.; Raz, Y.; Chen, R.; Shifrut, E.; Jacoby, E.; Milyavsky, M.

2026-03-18 cell biology
10.64898/2026.03.17.712280 bioRxiv
Show abstract

Prolonged cytopenias are a frequent complication of chimeric antigen receptor (CAR) T-cell therapies and are associated with increased infection risk and non-relapse mortality. Although inflammatory cytokines released during CAR-T cell activation have been implicated in immune effector cell-associated hematotoxicity (ICAHT), their direct effects on human hematopoietic stem and progenitor cells' (HSPCs) function remains incompletely understood. Here, we established a reductionist model of CAR-T-associated hematotoxicity using conditioned media (CM) derived from activated CD19 CAR-T cells. Sustained exposure of human HSPCs to CAR-T-derived inflammatory secretome impaired HSPC expansion and reduced long-term repopulating capacity in xenotransplantation assays. In contrast, short-term exposure did not abrogate HSPC function, indicating that brief inflammatory signals can initiate durable reprogramming events, with functional consequences emerging during subsequent proliferative expansion. Mechanistically, CAR-T CM induced IFN gamma- (IFNg) and TNF alpha- (TNFa) responsive transcriptional programs in HSPCs and promoted inflammatory myeloid skewing without evidence of apoptosis-dependent stem cell loss. Combined inhibition of IFNg and TNFa restored HSPC expansion, normalized lineage output, reversed inflammatory transcriptional signatures, and rescued in vivo repopulating capacity without impairing CAR-T cytotoxic activity. These findings demonstrate that CAR-T-derived inflammatory signaling can directly impair human HSC function and identify dual IFNg/TNFa blockade as a potential strategy to mitigate CAR-T-associated hematotoxicity while preserving antitumor efficacy.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Blood
67 papers in training set
Top 0.1%
14.8%
2
Blood Advances
54 papers in training set
Top 0.1%
12.4%
3
Haematologica
24 papers in training set
Top 0.1%
10.2%
4
Cell Stem Cell
57 papers in training set
Top 0.1%
9.2%
5
Stem Cell Reports
118 papers in training set
Top 0.2%
3.7%
50% of probability mass above
6
JCI Insight
241 papers in training set
Top 1%
3.7%
7
Stem Cells
28 papers in training set
Top 0.1%
3.6%
8
Nature Communications
4913 papers in training set
Top 39%
3.6%
9
Cell Reports
1338 papers in training set
Top 19%
2.6%
10
eLife
5422 papers in training set
Top 34%
2.4%
11
Journal of Clinical Investigation
164 papers in training set
Top 2%
2.1%
12
Journal of Experimental Medicine
106 papers in training set
Top 2%
1.9%
13
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
14
Science Advances
1098 papers in training set
Top 21%
1.3%
15
Leukemia
39 papers in training set
Top 0.6%
1.3%
16
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.8%
1.2%
17
Experimental Hematology
11 papers in training set
Top 0.2%
1.2%
18
Science Translational Medicine
111 papers in training set
Top 5%
0.9%
19
Stem Cell Research & Therapy
30 papers in training set
Top 0.7%
0.8%
20
Scientific Reports
3102 papers in training set
Top 74%
0.8%
21
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
22
Nature Medicine
117 papers in training set
Top 6%
0.6%
23
iScience
1063 papers in training set
Top 37%
0.6%
24
Cancer Discovery
61 papers in training set
Top 2%
0.6%
25
Gastroenterology
40 papers in training set
Top 2%
0.6%
26
Frontiers in Immunology
586 papers in training set
Top 10%
0.5%
27
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.9%
0.5%
28
Cytotherapy
14 papers in training set
Top 0.5%
0.5%
29
Stem Cells Translational Medicine
11 papers in training set
Top 0.3%
0.5%
30
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 12%
0.5%